{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:49:26Z","timestamp":1773874166791,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s11899-020-00590-5","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T14:03:27Z","timestamp":1591884207000},"page":"316-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma"],"prefix":"10.1007","volume":"15","author":[{"given":"Andrew M.","family":"Rogers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Brammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"issue":"20","key":"590_CR1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"25","key":"590_CR2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"\u2022 Vose J, et al. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330. This study is an important study to understand the long-term prognosis of patients with PTCL as it is the largest cohort of PTCL patients published to date.","journal-title":"J Clin Oncol"},{"issue":"9","key":"590_CR3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","volume":"129","author":"A Broccoli","year":"2017","unstructured":"Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood. 2017;129(9):1103\u201312.","journal-title":"Blood"},{"issue":"9","key":"590_CR4","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood-2016-09-692541","volume":"129","author":"MA Lunning","year":"2017","unstructured":"Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017;129(9):1095\u2013102.","journal-title":"Blood"},{"issue":"9","key":"590_CR5","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","volume":"129","author":"T Girardi","year":"2017","unstructured":"Girardi T, Vicente C, Cools J, de Keersmaecker K. The genetics and molecular biology of T-ALL. Blood. 2017;129(9):1113\u201323.","journal-title":"Blood"},{"issue":"1","key":"590_CR6","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Bri\u00e8re J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood. 1998;92(1):76\u201382.","journal-title":"Blood"},{"issue":"18","key":"590_CR7","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418\u201325.","journal-title":"Blood"},{"issue":"10168","key":"590_CR8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340.","journal-title":"Lancet"},{"issue":"2","key":"590_CR9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.6004\/jnccn.2018.0007","volume":"16","author":"SM Horwitz","year":"2018","unstructured":"Horwitz SM, Ansell SM, Ai WZ, Barnes J, Barta SK, Choi M, et al. NCCN guidelines insights: T-cell lymphomas, version 2.2018. J Natl Compr Cancer Netw. 2018;16(2):123\u201335.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"11","key":"590_CR10","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: an international collaborative effort on behalf of the guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23(11):1826\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 5","key":"590_CR11","doi-asserted-by":"crossref","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F d\u2019Amore","year":"2015","unstructured":"d\u2019Amore F, Gaulard P, Tr\u00fcmper L, Corradini P, Kim WS, Specht L, et al. Peripheral T-cell lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108\u201315.","journal-title":"Ann Oncol"},{"issue":"3","key":"590_CR12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","volume":"29","author":"G Fossard","year":"2018","unstructured":"Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29(3):715\u201323.","journal-title":"Ann Oncol"},{"issue":"12","key":"590_CR13","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1080\/10428194.2017.1300888","volume":"58","author":"H Cederleuf","year":"2017","unstructured":"Cederleuf H, Hjort Jakobsen L, Ellin F, de Nully Brown P, Stauffer Larsen T, B\u00f8gsted M, et al. Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. Leuk Lymphoma. 2017;58(12):2815\u201323.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"590_CR14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ajh.24372","volume":"91","author":"C Yam","year":"2016","unstructured":"Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, et al. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol. 2016;91(7):672\u20136.","journal-title":"Am J Hematol"},{"issue":"10","key":"590_CR15","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570\u20137.","journal-title":"Blood"},{"issue":"11","key":"590_CR16","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","volume":"25","author":"JS Abramson","year":"2014","unstructured":"Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211\u20137.","journal-title":"Ann Oncol"},{"issue":"1","key":"590_CR17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12185-013-1465-y","volume":"99","author":"L Gui","year":"2014","unstructured":"Gui L, Shi YK, He XH, Lei YH, Zhang HZ, Han XH, et al. High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis. Int J Hematol. 2014;99(1):69\u201378.","journal-title":"Int J Hematol"},{"issue":"6","key":"590_CR18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00277-013-1685-5","volume":"92","author":"JS Ahn","year":"2013","unstructured":"Ahn JS, Yang DH, Jung SH, Chae YS, Sohn SK, Yhim HY, et al. Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial. Ann Hematol. 2013;92(6):789\u201397.","journal-title":"Ann Hematol"},{"issue":"6","key":"590_CR19","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","volume":"13","author":"N Mehta","year":"2013","unstructured":"Mehta N, Maragulia JC, Moskowitz A, Hamlin PA, Lunning MA, Moskowitz CH, et al. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk. 2013;13(6):664\u201370.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"590_CR20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bmt.2009.165","volume":"45","author":"A Numata","year":"2010","unstructured":"Numata A, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 2010;45(2):311\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"590_CR21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","volume":"18","author":"J Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez J, Conde E, Guti\u00e9rrez A, Arranz R, Le\u00f3n \u00c1, Mar\u00edn J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18(4):652\u20137.","journal-title":"Ann Oncol"},{"issue":"5","key":"590_CR22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","volume":"40","author":"S Feyler","year":"2007","unstructured":"Feyler S, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007;40(5):443\u201350.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"590_CR23","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/annonc\/mdh471","volume":"15","author":"N Mounier","year":"2004","unstructured":"Mounier N, Gisselbrecht C, Bri\u00e8re J, Haioun C, Feugier P, Offner F, et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA). Ann Oncol. 2004;15(12):1790\u20137.","journal-title":"Ann Oncol"},{"issue":"25","key":"590_CR24","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"\u2022 Smith SM, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31(25):3100\u20139. Retrospective analysis of CIBMTR data regarding outcomes with autoHCT and alloHCT for the treatment of PTCL. This represents the largest retrospective study of alloHCT to date and highlights the potential benefits (PFS) and risks (NRM) of this treatment modality.","journal-title":"J Clin Oncol"},{"issue":"5","key":"590_CR25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","volume":"21","author":"A Beitinjaneh","year":"2015","unstructured":"Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015;21(5):855\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"590_CR26","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","volume":"20","author":"P Corradini","year":"2006","unstructured":"Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20(9):1533\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"590_CR27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","volume":"79","author":"J Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez J, Conde E, Guti\u00e9rrez A, Arranz R, Le\u00f3n \u00c1, Mar\u00edn J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo Study Group. Eur J Haematol. 2007;79(1):32\u20138.","journal-title":"Eur J Haematol"},{"issue":"5","key":"590_CR28","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","volume":"19","author":"S Mercadal","year":"2008","unstructured":"Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, et al. Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19(5):958\u201363.","journal-title":"Ann Oncol"},{"issue":"1","key":"590_CR29","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, R\u00fcdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106\u201313.","journal-title":"J Clin Oncol"},{"issue":"7","key":"590_CR30","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1038\/bcj.2016.63","volume":"6","author":"M Wilhelm","year":"2016","unstructured":"Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J. 2016;6(7):e452.","journal-title":"Blood Cancer J"},{"issue":"25","key":"590_CR31","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"\u2022\u2022 d\u2019Amore F, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093\u20139. This represents the largest prospective study of autoHCT as frontline consolidation therapy for PTCL to date and forms the basis for much of the current recommendations for frontline autograft in PTCL.","journal-title":"J Clin Oncol"},{"issue":"9","key":"590_CR32","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","volume":"28","author":"P Corradini","year":"2014","unstructured":"Corradini P, et al. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014;28(9):1885\u201391.","journal-title":"Leukemia"},{"issue":"15","key":"590_CR33","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2019.37.15_suppl.7503","volume":"37","author":"N Schmitz","year":"2019","unstructured":"Schmitz N, et al. First-line therapy of T-cell lymphoma: allogeneic or autologous transplantation for consolidation--final results of the AATT study. J Clin Oncol. 2019;37(15):7503.","journal-title":"J Clin Oncol"},{"issue":"3","key":"590_CR34","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajh.24992","volume":"93","author":"JY Zhang","year":"2018","unstructured":"Zhang JY, Briski R, Devata S, Kaminski MS, Phillips TJ, Mayer TL, et al. Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL). Am J Hematol. 2018;93(3):394\u2013400.","journal-title":"Am J Hematol"},{"issue":"17","key":"590_CR35","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/cncr.30100","volume":"122","author":"Y Nieto","year":"2016","unstructured":"Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, et al. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016;122(17):2680\u20138.","journal-title":"Cancer"},{"key":"590_CR36","doi-asserted-by":"crossref","unstructured":"Khan N, et al. A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma. Blood. 2019;134:4033.","DOI":"10.1182\/blood-2019-124179"},{"issue":"12","key":"590_CR37","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/bmt.2016.227","volume":"51","author":"J Gauthier","year":"2016","unstructured":"Gauthier J, Holmberg L, Wu D, Bensinger W, Gopal AK, Press O, et al. Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-cell lymphomas. Bone Marrow Transplant. 2016;51(12):1617\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"590_CR38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2013-09-526202","volume":"123","author":"C Damm-Welk","year":"2014","unstructured":"Damm-Welk C, Mussolin L, Zimmermann M, Pillon M, Klapper W, Oschlies I, et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2014;123(3):334\u20137.","journal-title":"Blood"},{"key":"590_CR39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2019-122781","volume":"134","author":"KJ Savage","year":"2019","unstructured":"\u2022 Savage KJ, et al. An exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): impact of consolidative stem cell transplant. Blood. 2019;134:464. Exploratory analysis of data from the ECHELON-2 trial suggesting benefit from consolidative autoHCT for patients in CR1 who were treated with a BV-containing regimen. This represents the first study using a BV-based induction followed by autoHCT consolidation.","journal-title":"Blood"},{"key":"590_CR40","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/blood-2019-123166","volume":"134","author":"AF Herrera","year":"2019","unstructured":"Herrera AF, Zain J, Savage KJ, Feldman TA, Brammer JE, Chen L, et al. Preliminary results from a phase 2 trial of brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-positive peripheral T-cell lymphomas. Blood. 2019;134:4023.","journal-title":"Blood"},{"issue":"7","key":"590_CR41","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","volume":"14","author":"AI Chen","year":"2008","unstructured":"Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008;14(7):741\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"590_CR42","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","volume":"14","author":"J Rodr\u00edguez","year":"2003","unstructured":"Rodr\u00edguez J, Caballero MD, Guti\u00e9rrez A, Mar\u00edn J, Lahuerta JJ, Sureda A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14(12):1768\u201375.","journal-title":"Ann Oncol"},{"issue":"2","key":"590_CR43","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","volume":"134","author":"T Kewalramani","year":"2006","unstructured":"Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 2006;134(2):202\u20137.","journal-title":"Br J Haematol"},{"issue":"6","key":"590_CR44","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41409-018-0360-9","volume":"54","author":"G Wulf","year":"2019","unstructured":"Wulf G, Hasenkamp J, Jung W, Wilhelm C, Held G, Nickelsen M, et al. Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease. Bone Marrow Transplant. 2019;54(6):877\u201384.","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"590_CR45","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.bbmt.2013.07.003","volume":"19","author":"A Czajczynska","year":"2013","unstructured":"Czajczynska A, G\u00fcnther A, Repp R, Humpe A, Schub N, Raff T, et al. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin\u2019s lymphoma. Biol Blood Marrow Transplant. 2013;19(11):1632\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"590_CR46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/bmt.2011.16","volume":"47","author":"M Delioukina","year":"2012","unstructured":"Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant. 2012;47(1):65\u201372.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"590_CR47","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2011.240","volume":"26","author":"A Dodero","year":"2012","unstructured":"Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26(3):520\u20136.","journal-title":"Leukemia"},{"issue":"7","key":"590_CR48","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","volume":"22","author":"ED Jacobsen","year":"2011","unstructured":"Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome. Ann Oncol. 2011;22(7):1608\u201313.","journal-title":"Ann Oncol"},{"issue":"8","key":"590_CR49","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3109\/10428194.2011.574754","volume":"52","author":"J Zain","year":"2011","unstructured":"Zain J, Palmer JM, Delioukina M, Thomas S, Tsai NC, Nademanee A, et al. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma. 2011;52(8):1463\u201373.","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"590_CR50","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2141.2010.08210.x","volume":"150","author":"AR Shustov","year":"2010","unstructured":"Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol. 2010;150(2):170\u20138.","journal-title":"Br J Haematol"},{"issue":"24","key":"590_CR51","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","volume":"27","author":"C Kyriakou","year":"2009","unstructured":"Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2009;27(24):3951\u20138.","journal-title":"J Clin Oncol"},{"issue":"14","key":"590_CR52","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Le Gouill","year":"2008","unstructured":"Le Gouill S, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire. J Clin Oncol. 2008;26(14):2264\u201371.","journal-title":"J Clin Oncol"},{"key":"590_CR53","unstructured":"Hosing C, et al. Romidepsin (Rom) in combination with fludarabine (Flu) and busulfan (Bu) conditioning followed by Rom maintenance in patients with T-cell malignancies receiving allogeneic stem cell transplant (allo-SCT): early results of a phase I\/II trial. T-Cell Lymphoma forum. La Jolla, CA. 2020. Abstract 40."},{"issue":"26","key":"590_CR54","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"1","key":"590_CR55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk J, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"11","key":"590_CR56","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1172\/JCI43437","volume":"120","author":"M Leisegang","year":"2010","unstructured":"Leisegang M, Wilde S, Spranger S, Milosevic S, Frankenberger B, Uckert W, et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest. 2010;120(11):3869\u201377.","journal-title":"J Clin Invest"},{"issue":"10","key":"590_CR57","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499\u2013503.","journal-title":"Nat Med"},{"issue":"6","key":"590_CR58","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/smim.1998.0156","volume":"10","author":"R Horie","year":"1998","unstructured":"Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10(6):457\u201370.","journal-title":"Semin Immunol"},{"issue":"1","key":"590_CR59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12885-019-5415-9","volume":"19","author":"NS Grover","year":"2019","unstructured":"Grover NS, Savoldo B. Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer. 2019;19(1):203.","journal-title":"BMC Cancer"},{"issue":"9","key":"590_CR60","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462\u201371.","journal-title":"J Clin Invest"},{"issue":"5","key":"590_CR61","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"CM Wang","year":"2017","unstructured":"Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23(5):1156\u201366.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"590_CR62","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.bbmt.2018.12.145","volume":"25","author":"CA Ramos","year":"2019","unstructured":"Ramos CA, Bilgi M, Gerken C, Dakhova O, Mei Z, Wu MF, et al. CD30-chimeric antigen receptor (CAR) T cells for therapy of Hodgkin lymphoma (HL). Biol Blood Marrow Transplant. 2019;25(3):S63.","journal-title":"Biol Blood Marrow Transplant"},{"key":"590_CR63","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2018-99-113534","volume":"132","author":"NS Grover","year":"2018","unstructured":"Grover NS, Park SI, Ivanova A, Eldridge P, McKay K, Cheng CJA, et al. Clinical responses to CAR.CD30-T cells in patients with CD30+ lymphomas relapsed after multiple treatments including brentuximab vedotin. Blood. 2018;132:681.","journal-title":"Blood"},{"key":"590_CR64","unstructured":"Beaven A. CD30 CART in PTCL. Oral presentation. T-Cell Lymphoma Forum. La Jolla, CA. 2020."},{"issue":"9","key":"590_CR65","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.4049\/jimmunol.170.9.4623","volume":"170","author":"C Brossard","year":"2003","unstructured":"Brossard C, Semichon M, Trautmann A, Bismuth G. CD5 inhibits signaling at the immunological synapse without impairing its formation. J Immunol. 2003;170(9):4623\u20139.","journal-title":"J Immunol"},{"issue":"3","key":"590_CR66","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1073\/pnas.78.3.1791","volume":"78","author":"EG Engleman","year":"1981","unstructured":"Engleman EG, Warnke R, Fox RI, Dilley J, Benike CJ, Levy R. Studies of a human T lymphocyte antigen recognized by a monoclonal antibody. Proc Natl Acad Sci. 1981;78(3):1791\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"6086","key":"590_CR67","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/323346a0","volume":"323","author":"NH Jones","year":"1986","unstructured":"Jones NH, Clabby ML, Dialynas DP, Huang HJS, Herzenberg LA, Strominger JL. Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1\/Leu-1. Nature. 1986;323(6086):346\u20139.","journal-title":"Nature"},{"issue":"4","key":"590_CR68","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1309\/QF6N-VAQW-N74H-4JE2","volume":"116","author":"S Jamal","year":"2001","unstructured":"Jamal S, Picker LJ, Aquino DB, McKenna RW, Dawson DB, Kroft SH. Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter flow cytometric approach. Am J Clin Pathol. 2001;116(4):512\u201326.","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"590_CR69","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1182\/blood.V78.5.1173.1173","volume":"78","author":"CF LeMaistre","year":"1991","unstructured":"LeMaistre CF, et al. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood. 1991;78(5):1173\u201382.","journal-title":"Blood"},{"issue":"8","key":"590_CR70","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126(8):983\u201392.","journal-title":"Blood"},{"key":"590_CR71","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","volume":"134","author":"LC Hill","year":"2019","unstructured":"Hill LC, Rouce RH, Smith TS, Yang L, Srinivasan M, Zhang H, et al. Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed\/refractory T-cell malignancies. Blood. 2019;134:199.","journal-title":"Blood"},{"issue":"2","key":"590_CR72","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4049\/jimmunol.152.2.517","volume":"152","author":"H Rabinowich","year":"1994","unstructured":"Rabinowich H, et al. Expression and function of CD7 molecule on human natural killer cells. J Immunol. 1994;152(2):517\u201326.","journal-title":"J Immunol"},{"issue":"2","key":"590_CR73","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/eji.1830250229","volume":"25","author":"SG Ward","year":"1995","unstructured":"Ward SG, Parry R, Lefeuvre C, Sansom DM, Westwick J, Lazarovits AI. Antibody ligation of CD7 leads to association with phosphoinositide 3-kinase and phosphatidylinositol 3,4,5-trisphosphate formation in T lymphocytes. Eur J Immunol. 1995;25(2):502\u20137.","journal-title":"Eur J Immunol"},{"issue":"2","key":"590_CR74","doi-asserted-by":"crossref","first-page":"934","DOI":"10.4049\/jimmunol.159.2.934","volume":"159","author":"AS Chan","year":"1997","unstructured":"Chan AS, et al. CD7-mediated regulation of integrin adhesiveness on human T cells involves tyrosine phosphorylation-dependent activation of phosphatidylinositol 3-kinase. J Immunol. 1997;159(2):934\u201342.","journal-title":"J Immunol"},{"issue":"25","key":"590_CR75","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 2017;1(25):2348\u201360.","journal-title":"Blood Adv"},{"issue":"3","key":"590_CR76","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130(3):285\u201396.","journal-title":"Blood"},{"issue":"9","key":"590_CR77","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","volume":"32","author":"ML Cooper","year":"2018","unstructured":"Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, et al. An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018;32(9):1970\u201383.","journal-title":"Leukemia"},{"issue":"5994","key":"590_CR78","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/312541a0","volume":"312","author":"JE Sims","year":"1984","unstructured":"Sims JE, Tunnacliffe A, Smith WJ, Rabbitts TH. Complexity of human T-cell antigen receptor beta-chain constant- and variable-region genes. Nature. 1984;312(5994):541\u20135.","journal-title":"Nature"},{"issue":"15","key":"590_CR79","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1073\/pnas.82.15.5068","volume":"82","author":"A Tunnacliffe","year":"1985","unstructured":"Tunnacliffe A, Kefford R, Milstein C, Forster A, Rabbitts TH. Sequence and evolution of the human T-cell antigen receptor beta-chain genes. Proc Natl Acad Sci U S A. 1985;82(15):5068\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"590_CR80","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","volume":"23","author":"PM Maciocia","year":"2017","unstructured":"\u2022\u2022 Maciocia PM, et al. Targeting the T cell receptor \u03b2-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017;23(12):1416\u201323. This study forms the basis of the development of a CART therapy directed towards the T-cell receptor for patients with T-cell lymphoma\/leukemia.","journal-title":"Nat Med"},{"key":"590_CR81","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/blood-2018-99-119564","volume":"132","author":"S Onuoha","year":"2018","unstructured":"Onuoha S, Ferrari M, Bulek A, Bughda R, Manzoor S, Srivastava S, et al. Structure guided engineering of highly specific chimeric antigen receptors for the treatment of T cell lymphomas. Blood. 2018;132:1661.","journal-title":"Blood"},{"issue":"1","key":"590_CR82","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/imr.12793","volume":"290","author":"DA Lee","year":"2019","unstructured":"Lee DA. Cellular therapy: adoptive immunotherapy with expanded natural killer cells. Immunol Rev. 2019;290(1):85\u201399.","journal-title":"Immunol Rev"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00590-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-020-00590-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00590-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T12:24:08Z","timestamp":1723033448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-020-00590-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["590"],"URL":"https:\/\/doi.org\/10.1007\/s11899-020-00590-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"11 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center For Advancing Translational Sciences or the National Institutes of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"J.E.B. has received honoraria from Seattle Genetics (Speaker\u2019s Bureau, Ad Board) and research funding from Celgene (now Bristol-Myers-Squibb).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}